BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Vetter starts construction of new facility in Germany for production of injectable drugs

May 14, 2026 | News

Strategic investments in the EU and US strengthen Vetterâ??s global footprint



Vetter, a leading Contract Development and Manufacturing Organization (CDMO), has announced the start of construction on its new site in Saarlouis with a traditional groundbreaking ceremony. During the first construction phase, the company will build a state-of-the-art facility for the commercial production of injectable drugs on the 95-acre industrial site.

In total, Vetter will invest almost half a billion euros in the site by the planned commissioning in 2031, underscoring its role as an industry leader for quality and technology. Once operational, the facility will create 400 to 500 new jobs, a figure that could rise to 1,500 by the final stage of the first construction phase. Ultimately, up to 2,000 jobs could be created.

In the first expansion phase, Vetter will build a 50,000 sqm manufacturing site, along with production-related facilities including laboratories and warehouses. Initially, three state-of-the-art cleanrooms are planned for the aseptic production of innovative and complex drug products: two for filling pre-sterilized syringes and one for filling vials.

Udo J. Vetter, Chairman of the Advisory Board and member of the owner family said, "Today's groundbreaking ceremony marks a decisive step for the future of our family business. With our new location in Saarlouis, we are setting the course for further sustainable growth. We are creating the conditions to further expand our capacities in the field of complex drug product manufacturing. This underlines our continuous approach to offer our international customers the resources, quality and reliability they need and are accustomed to from us."